Novozymes CFO: We have outperformed our expectations
Byproducts and innovation continue to propel the bioenergy division, with higher prices also helping to secure growth.
2023 has kicked off ablaze in the bioenergy division at Novozymes, and the reason for this is partly due to the company’s innovation, says Lars Green, CFO of Novozymes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bioenergy saves Novozymes in the second quarter
For subscribers
.jpg&w=384&q=75){kind=logo}